Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India.
Technical Expert (Zoology), Haryana State Biodiversity Board, Panchkula,Haryana, India.
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):2157-2170. doi: 10.31557/APJCP.2023.24.6.2157.
The present study aimed to provide an insight into the acute toxicity of a novel fluorinated nucleoside analogue (FNA), FNC (Azvudine or2'-deoxy-2'-β-fluoro-4'-azidocytidine). FNC showed potent anti-viral and anti-cancer activities and approved drug for high-load HIV patients, despite, its acute toxicity study being lacking.
OECD-423 guidelines were followed during this study and the parameters were divided into four categories - behavioral parameters, physiological parameters, histopathological parameters, and supplementary tests. The behavioral parameters included feeding, body weight, belly size, organ weight and size, and mice behavior. The physiological parameters consisted of blood, liver, and kidney indicators. In histopathological parameters hematoxylin and eosin staining was performed to analyse the histological changes in the mice organs after FNC exposure. In addition, supplementary tests were conducted to assess cellular viability, DNA fragmentation and cytokine levels (IL-6 and TNF-α) in response to FNC.
In the behavioral parameters FNC induced changes in the mice-to-mice interaction and activities. Mice's body weight, belly size, organ weight, and size remained unchanged. Physiological parameters of blood showed that FNC increased the level of WBC, RBC, Hb, and neutrophils and decreased the % count of lymphocytes. Liver enzymes SGOT (AST), and ALP was increased. In the renal function test (RFT) cholesterol level was significantly decreased. Histopathological analysis of the liver, kidney, brain, heart, lungs, and spleen showed no sign of tissue damage at the highest FNC dose of 25 mg/kg b.wt. Supplementary tests for cell viability showed no change in viability footprint, through our recently developed dilution cum-trypan (DCT) assay, and Annexin/PI. No DNA damage or apoptosis was observed in DAPI or AO/EtBr studies. Pro-inflammatory cytokines IL-6 and TNF-α increased in a dose-dependent manner.
This study concluded that FNC is safe to use though higher concentration shows slight toxicity.
本研究旨在深入了解新型氟核苷类似物(FNA)FNC(阿昔洛韦或 2'-脱氧-2'-β-氟-4'-叠氮胞苷)的急性毒性。尽管 FNC 具有很强的抗病毒和抗癌活性,并已被批准用于高病毒载量的 HIV 患者,但目前仍缺乏其急性毒性研究。
本研究遵循 OECD-423 指南,将参数分为四类 - 行为参数、生理参数、组织病理学参数和补充测试。行为参数包括摄食、体重、腹部大小、器官重量和大小以及小鼠行为。生理参数包括血液、肝脏和肾脏指标。在组织病理学参数中,进行苏木精和伊红染色以分析 FNC 暴露后小鼠器官的组织学变化。此外,还进行了补充测试,以评估细胞活力、DNA 片段化和细胞因子水平(IL-6 和 TNF-α)对 FNC 的反应。
在行为参数方面,FNC 诱导了小鼠之间的相互作用和活动的变化。小鼠的体重、腹部大小、器官重量和大小保持不变。血液生理参数显示,FNC 增加了白细胞、红细胞、血红蛋白和中性粒细胞的水平,并降低了淋巴细胞的%计数。肝酶 SGOT(AST)和 ALP 增加。在肾功能测试(RFT)中,胆固醇水平显著降低。对肝脏、肾脏、大脑、心脏、肺和脾脏的组织病理学分析表明,在最高剂量 25mg/kg b.wt 的 FNC 下,没有组织损伤的迹象。通过我们最近开发的稀释 cum-台盼蓝(DCT)测定法和 Annexin/PI,补充的细胞活力测试显示没有活力足迹的变化。在 DAPI 或 AO/EtBr 研究中未观察到 DNA 损伤或细胞凋亡。促炎细胞因子 IL-6 和 TNF-α呈剂量依赖性增加。
本研究得出结论,尽管高浓度的 FNC 显示出轻微的毒性,但它是安全的。